减重26.6%，效果顶尖的替尔泊肽能否替代减重手术？

Core Viewpoint - Tirzepatide is a rapidly advancing GLP-1/GIP dual receptor agonist that shows superior efficacy in controlling blood sugar and weight loss compared to the GLP-1 receptor agonist Semaglutide, raising the question of whether it could replace weight loss surgery [2][6] Group 1: Market Trends and Impact - The approval of Wegovy in mid-2021 has led to a surge in sales of GLP-1 drugs like Ozempic, Mounjaro, and Zepbound, significantly changing the landscape of weight management [2] - A study published in JAMA Network Open indicates that the proportion of patients receiving GLP-1 RA treatment for obesity increased by 132.6% from the last six months of 2022 to the last six months of 2023 [3] - In contrast, the proportion of patients undergoing metabolic weight loss surgery decreased by 25.6% during the same period, highlighting a shift towards non-surgical weight management options [5] Group 2: Efficacy of Tirzepatide vs. Weight Loss Surgery - Sleeve gastrectomy, the most common metabolic weight loss surgery, has an average weight loss rate of only 25.2% after one year, while Tirzepatide achieves a weight loss of 26.6% (29.2 kg) [6][10] - Clinical trials such as SURMOUNT-1 and SURMOUNT-2 demonstrate that Tirzepatide significantly outperforms Semaglutide in weight loss, with patients losing an average of 50.3 pounds (22.8 kg) compared to 33.1 pounds (15.0 kg) for Semaglutide [11] Group 3: Safety Profile - Weight loss surgery carries risks of complications such as acid reflux, chronic nausea, and infections, whereas Tirzepatide presents a safer alternative with a lower incidence of severe side effects [13] - Approximately 80% of Tirzepatide users report at least one side effect, primarily gastrointestinal, but these are generally less severe compared to those associated with Semaglutide [15]